Switched to Cost Plus Drugs at 25 mg PO once daily for Eplerenone; monthly out-of-pocket dropped to $16.63 compared with $142.00 retail.
Eplerenone
Brand Reference: Inspra
Eplerenone Clinical & Real-World Cost Fact Matrix
| Metric | Verified Benchmark | Source |
|---|---|---|
| Eplerenone RxNorm Concept ID | 298869 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.5800 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $142.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $18.90 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $22.00 / mo | 14 Zero-PHI Verified Patient Logs |
Verified Online Prescribers & Wholesale Pharmacies for Eplerenone
Eplerenone Clinical Pharmacology & DailyMed Monograph
RxCUI 298869 • NDC 00378-6525-939,11-epoxy steroid that selectively blocks aldosterone binding at renal and vascular mineralocorticoid receptors with >100-fold lower affinity for androgen and progesterone receptors than spironolactone, preventing myocardial fibrosis without gynecomastia.
Across 14 community cost disclosures for Eplerenone (Inspra), cash buyers routing around $142.00 retail markups capture a 87% discount ($18.90/mo benchmark vs $0.5800 NADAC acquisition).
Following administration (25 mg PO once daily), Eplerenone achieves 69% oral bioavailability and 1.5 hours cmax; 4 weeks full vascular effect onset, governed by a 4–6 hours terminal half-life through hepatic cyp3a4 oxidation to inactive open-lactone metabolites.
Before initiating Eplerenone at 25 mg PO once daily, clinical safety checklists rule out baseline serum potassium > 5.5 meq/l; creatinine clearance <= 30 ml/min; concomitant strong cyp3a4 inhibitors. Logged tolerability patterns center on mild k+ elevation (9% of reports), dizziness (5% of reports).
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Baseline serum potassium > 5.5 mEq/L
- Creatinine clearance <= 30 mL/min
- Concomitant strong CYP3A4 inhibitors
Logged Side-Effect Incidence (14 Reports)
Eplerenone Patient Dosage Logs & Out-of-Pocket Cost Ledger
Across 14 verified cash-pay logs, Eplerenone achieves a 88.30% Worth-It rating with out-of-pocket spend averaging $22.00/mo versus $142.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Completed 10 weeks on Eplerenone (50 mg PO once daily). Zero notable side effects on steady dosing.
Consistent biomarker response on 25 mg PO twice daily Eplerenone sourced via Compounding ($21.92/mo cash pay without insurance prior authorization).